Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Azvudine Meta Metformin Meta
Bromhexine Meta
Budesonide Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Famotidine Meta Nitazoxanide Meta
Favipiravir Meta Paxlovid Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 50% Improvement Relative Risk Ivermectin for COVID-19  Ahsan et al.  LATE TREATMENT Is late treatment with ivermectin + doxycycline beneficial for COVID-19? Retrospective 165 patients in Pakistan Lower mortality with ivermectin + doxycycline (p=0.025) Ahsan et al., Cureus, April 2021 Favors ivermectin Favors control

Clinical Variants, Characteristics, and Outcomes Among COVID-19 Patients: A Case Series Analysis at a Tertiary Care Hospital in Karachi, Pakistan

Ahsan et al., Cureus, doi:10.7759/cureus.14761
Apr 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 165 hospitalized patients in Pakistan showing unadjusted lower mortality with combined ivermectin and doxycycline treatment. Details of the ivermectin group compared to other patients are not provided, however ivermectin was given to a similar percentage of patients in the mild, moderate, and severe/critical groups (34.5%, 29.1%, and 36.4%), suggesting that ivermectin treatment was not based on severity.
This is the 51st of 99 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 2 sextillion). 46 studies are RCTs, which show efficacy with p=0.00000014.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 50.0% lower, RR 0.50, p = 0.03, treatment 17 of 110 (15.5%), control 17 of 55 (30.9%), NNT 6.5.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ahsan et al., 29 Apr 2021, retrospective, Pakistan, peer-reviewed, 10 authors, dosage 150μg/kg days 1-2, 150-200µg/kg, this trial uses multiple treatments in the treatment arm (combined with doxycycline) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Clinical Variants, Characteristics, and Outcomes Among COVID-19 Patients: A Case Series Analysis at a Tertiary Care Hospital in Karachi, Pakistan
Tasnim Ahsan, Bharta Rani, Glenis Roomana Siddiqui, Glenis D‘souza, Razzaq Memon, Irfan Lutfi, Omer I. Hasan, Rushma Javed, Farhan Khan, Muhammad Hassan
Cureus, doi:10.7759/cureus.14761
Introduction Coronavirus disease 2019 has become a global threat to public health. The current study investigates alterations in the biological estimates concerning the severity, recovery, mortality, and assessment of treatment-based outcomes. Methods A case series of 165 COVID-19 patients admitted to OMI Institute (a tertiary care hospital) was conducted between May and August 2020. The data regarding demographic characteristics, comorbid conditions, radiographic abnormalities, biological estimations, symptoms, treatment, disease progression, complications, and outcomes were recorded using a structured questionnaire. Laboratory estimations included complete blood count (CBC), renal and electrolyte profile, liver function tests (LFTs), hematological indices, and inflammatory markers. Chest X-ray, electrocardiogram (ECG), and a high-resolution computed tomography (HRCT) scan were also performed, and data were extracted from the medical records. Analysis was done using the Statistical Package for the Social Sciences (SPSS) version 22.0. Results Out of the 165 COVID-19 patients, 79.4% recovered and were successfully discharged, while 20.6% of inpatient died. The patients' mean age was 56.03 ± 15.96 years, with a male majority (55.1%). The most common comorbid conditions were diabetes and hypertension; fever and dry cough were among the most frequently reported symptoms. The chest imaging findings among the severe/critical COVID-19 patients showed extensive bilateral patchy opacities. The median laboratory investigations, including neutrophil-tolymphocyte ratio (NLR) (14.83), C-reactive protein (CRP) (7.4 mg/dl), lactate dehydrogenase (LDH) (786 IU/L), ferritin (1401.15 mcg/ml), and mean oxygen saturation (88.25%), were significantly altered among cases with increased disease severity and those who expired (p<0.05). The proportion of acute respiratory distress syndrome (ARDS) and sepsis development was significantly high among severe/critical COVID-19 patients (p<0.05). Treatment with tocilizumab, remdesivir, doxycycline, ivermectin, enoxaparin sodium, and steroids was deemed to be potentially effective treatment options in terms of reducing COVID-19 severity and chances of recovery. Furthermore, age (OR 1.05; p=0.047), presence of comorbidity (OR 8.471; p=0.004), high NLR, LDH (final outcome) (OR 1.361 and 1.018; p<0.05), and CRP levels (midpoint) (OR 1.631; p=0.05) were identified as the strong predictors of death among COVID-19 patients. Conclusion The study identified several alterations in the clinical profile of the COVID-19 patients concerning severity during the hospital stay, affecting prognosis. Clinically, tocilizumab, remdesivir, doxycycline, ivermectin, enoxaparin sodium, and steroids were identified as potential therapeutic options for COVID-19 due to their ability to alter disease-associated severity and recovery rate.
Additional Information Disclosures Human subjects: Consent was obtained or waived by all participants in this study. Medicell Institute of Diabetes, Endocrinology & Metabolism (MIDEM) issued approval IRB-005/MHS/20. The Independent Ethical Review Committee of Medicell Institute of Diabetes, Endocrinology & Metabolism (MIDEM) approved the study protocol (Reference no. IRB-005/MHS/20; Dated: 27th April 2020). Written informed consent was obtained from each patient or the next of kin before inclusion in the study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Adhikari, Meng, Wu, Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review, Infect Dis Poverty, doi:10.1186/s40249-020-00646-x
Asghar, Kazmi, Khan, Clinical profiles, characteristics, and outcomes of the first 100 admitted COVID-19 patients in Pakistan: a single-center retrospective study in a tertiary care hospital of Karachi, Cureus, doi:10.7759/cureus.c34
Beigel, Tomashek, Dodd, Remdesivir for the treatment of Covid-19 -final report, N Engl J Med, doi:10.1056/NEJMoa2007764
Ciccullo, Borghetti, Verme, Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line, Int J Antimicrob Agents
Duan, Liu, Li, Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc Natl Acad Sci U S A, doi:10.1073/pnas.2004168117
Falasca, Nardacci, Colombo, Postmortem findings in Italian patients with COVID-19: a descriptive full autopsy study of cases with and without comorbidities, J Infect Dis, doi:10.1093/infdis/jiaa578
Francone, Iafrate, Masci, Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis, Eur Radiol, doi:10.1007/s00330-020-07033-y
Horby, Campbell, Staplin, Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, doi:10.1101/2021.02.11.21249258
Jamwal, Bhatnagar, Sharma, Coronavirus disease 2019 (COVID-19): current literature and status in India, doi:10.20944/preprints202004.0189.v1
Jeronimo, Farias, Val, Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial, Clin Infect Dis, doi:10.1093/cid/ciaa1177
Khan Chachar, Khan, Khan, Clinical and demographic characteristics including comorbidities and their outcomes among patients hospitalized with COVID-19 in four tertiary care hospitals across Lahore, Cureus, doi:10.7759/cureus.12663
Khan, Saleem, Aziz, Psychological response & perceived risk associated with coronavirus disease, Ann Psychophysiol, doi:10.29052/2412-3188.v7.i1.2020.9-18
Liu, Li, Liu, Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients, EBioMedicine, doi:10.1016/j.ebiom.2020.102763
Mejía, Medina, Cornejo, Oxygen saturation as a predictor of mortality in hospitalized adult patients with COVID-19 in a public hospital in Lima, Peru, PLoS One, doi:10.1371/journal.pone.0244171
Mushtaq, Zafar Mahmood, Jamil, Aziz, Ali, Outcome of COVID-19 patients with use of Tocilizumab: a single center experience, Int Immunopharmacol, doi:10.1016/j.intimp.2020.106926
Riaz, Saleem, Hazrat, Ahmed, Sajid et al., Mental health outcomes and coping strategies among health care workers exposed to coronavirus disease 2019 (COVID-19), IJEHSR
Simonovich, Pratx, Scibona, A randomized trial of convalescent plasma in Covid-19 severe pneumonia, N Engl J Med, doi:10.1056/NEJMoa2031304
Su, Wong, Shi, Epidemiology, genetic recombination, and pathogenesis of coronaviruses, Trends Microbiol, doi:10.1016/j.tim.2016.03.003
Syed, Shamim, Zaidi, Past and current coronavirus outbreaks; focusing on coronavirus disease 2019 in comparison with severe acute respiratory syndrome and middle east respiratory syndrome, Int J Endorsing Health Sci Res, doi:10.29052/IJEHSR.v8.i3.2020.159-170
Wang, Zhang, Du, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, doi:10.1016/S0140-6736(20)31022-9
Wu, Chen, Cai, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Int Med, doi:10.1001/jamainternmed.2020.0994
Wu, Chen, Cai, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern Med, doi:10.1001/jamainternmed.2020.0994
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention, JAMA, doi:10.1001/jama.2020.2648
Zhou, Chen, Wang, Zhao, Wei et al., Low serum calcium: a new, important indicator of COVID-19 patients from mild/moderate to severe/critical, Biosci Rep, doi:10.1042/BSR20202690
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop